Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Dialysis research includes treatment-target achievement and an association between GLP-1 use and lower mortality.

Rhea-AI Summary

Fresenius Medical Care (FMS) is presenting kidney-care research at ASN Kidney Week, taking place October 21–25, 2026, in Denver.

A U.S. study covering more than 10,000 treatments found that 74% achieved the high-volume hemodiafiltration target of at least 23 liters of convective volume. An analysis of approximately 5,000 dialysis patients associated GLP-1 receptor agonist use with lower mortality and fewer hospitalizations. A multicenter U.S. study of continuous renal replacement therapy in critically ill patients reported maintained anticoagulation targets, infrequent, manageable electrolyte disturbances and no observed citrate toxicity.

Positive

• Minor pointHigh-volume hemodiafiltration achieved the 23-liter-or-greater target in 74% of more than 10,000 U.S. treatments.
• Minor pointGLP-1 use was associated with significantly lower mortality and fewer hospitalizations in approximately 5,000 dialysis patients.
• Minor pointIntegrated continuous renal replacement therapy maintained anticoagulation targets, with no observed citrate toxicity in critically ill patients.
• Minor pointAI analysis of more than 455,000 dialysis treatment notes demonstrated high accuracy extracting and classifying symptoms and signs.

Negative

• Minor pointRegional citrate anticoagulation study reported infrequent, manageable electrolyte disturbances in critically ill patients.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New U.S. real-world evidence demonstrates high-volume hemodiafiltration (HvHDF) can be successfully delivered in routine clinical practice, with treatment targets comparable to those reported in Europe
• GLP-1 receptor agonist use associated with significantly lower mortality and fewer hospitalizations among dialysis patients
• U.S. study reports clinical experience with automated regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients

BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

Company research demonstrates how real-world evidence, advanced technologies, and insights generated in routine clinical practice can help inform treatment decisions and improve care for patients with kidney disease.

"At Fresenius Medical Care, we are leveraging real-world evidence generated at scale to improve patient outcomes and help inform future standards of kidney care," said Charles Hugh-Jones, MD, FRCP, Global Chief Medical Officer of Fresenius Medical Care. "The studies we are presenting at Kidney Week 2026 reflect our commitment to advancing evidence-based care, from expanding our understanding of high-volume hemodiafiltration in U.S. clinical practice to generating new insights into therapies associated with improved outcomes for dialysis patients and supporting the safe delivery of renal replacement therapy in critical care settings."

As adoption of HvHDF continues to expand in the United States, Fresenius Medical Care researchers are studying its implementation in routine clinical practice. These studies provide important real-world insights from U.S. treatment settings and contribute to broader evidence-generation efforts, including the company's BEACON-US research initiative, which is advancing understanding of online HDF therapy and patient outcomes in the U.S.

Key Fresenius Medical Care presentations at Kidney Week 2026 include:

• High-Volume Hemodiafiltration in the United States: Real-World Achievement of Target Convective Dose: Demonstrates achievement of recommended HvHDF convective dose targets in a cohort of patients receiving more than 10,000 treatments using the 5008X™ CAREsystem in the U.S. The study found that 74% of treatments achieved the target threshold of 23 liters or greater.
  
  
• Convective Volume, Body Size and Mortality in Hemodiafiltration: An Individual Patient Data Analysis of Randomized Trials: Examines the relationship between body size, convective volume, and survival among patients receiving HDF and explores a more individualized approach to assessing effective HDF dose.
  
  
• Near-Real-Time Surveillance of U.S. 5008X High-Volume Hemodiafiltration: An Accelerated Real-World Evidence Platform: Highlights a quality improvement surveillance platform designed to rapidly analyze real-world clinical data during the U.S. rollout of HvHDF, helping researchers evaluate outcomes including mortality, hospitalization, and missed treatments.
  
  
• Real-World Mortality and Hospitalization Outcomes Associated with GLP-1 Receptor Agonist Use in Patients on Dialysis: Presents findings from an analysis of approximately 5,000 dialysis patients associating GLP-1 receptor agonist use with significantly lower mortality and fewer hospitalizations. A second GLP-1-related abstract, "GLP-1 Receptor Agonist Initiation and Mortality in Patients on Maintenance Hemodialysis: A Target Trial Emulation," was selected for presentation during the late-breaking research poster session on October 22 from 10 a.m. to noon.
  
  
• Calcium Control and Electrolyte Stability During Regional Citrate Anticoagulation Using a Fully Integrated CRRT System: Insights from a Prospective Multicenter Study: Reports findings from a multicenter U.S. study demonstrating that regional citrate anticoagulation delivered through an integrated continuous renal replacement therapy system maintained anticoagulation targets with infrequent, manageable electrolyte disturbances and no observed citrate toxicity in critically ill patients.
  
  
• AI-Based Extraction and Temporal Classification of Symptoms and Signs from Hemodialysis Notes: Evaluates a large language model-based approach using more than 455,000 dialysis treatment notes to extract and classify symptoms and clinical signs. The quality improvement effort demonstrated high accuracy and highlights how AI may help transform routine clinical documentation into actionable insights that support research, quality improvement, and future clinical decision-making.

In addition to scientific presentations, attendees can visit Fresenius Medical Care at Booth #571 and FME's Renal Research Institute at Booth #255 to learn more about the Company's latest research and innovations, including the 5008X CAREsystem and multiFiltratePRO™.

For more information on Fresenius Medical Care's presence at Kidney Week 2026, visit https://freseniusmedicalcare.com/en/media/events/asn-2026/.

About Fresenius Medical Care:

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,513 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contacts
Ryan Jimenez
T +1 781 699 3900
ryan.jimenez@freseniusmedicalcare.com

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-presents-new-evidence-and-innovations-advancing-kidney-care-at-asn-kidney-week-2026-302912336.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fresenius Medical Care's U.S. high-volume hemodiafiltration study find?

The study found that 74% of treatments achieved the target convective volume of 23 liters or greater. It covered a patient cohort receiving more than 10,000 treatments using the 5008X CAREsystem in the United States.

What did Fresenius Medical Care's GLP-1 analysis find in dialysis patients?

An analysis of approximately 5,000 dialysis patients associated GLP-1 receptor agonist use with significantly lower mortality and fewer hospitalizations. The findings describe an association, rather than establishing that the drugs caused those outcomes.

How is Fresenius Medical Care studying AI use in dialysis treatment notes?

A quality improvement effort evaluated a large language model using more than 455,000 dialysis treatment notes to extract and classify symptoms and clinical signs. It demonstrated high accuracy; the company said the approach may support research, quality improvement and future clinical decision-making.